Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study

BACKGROUND/AIMS: In Taiwan, due to budget limitations, the National Health Insurance only allows for a limited period of biologics use in treating moderate to severe Crohn's disease (CD). We aimed to access the outcomes of CD patients following a limited period use of biologics, specifically fo...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Intest Res
Главные авторы: Lin, Wei-Chen, Chou, Jen-Wei, Yen, Hsu-Heng, Hsu, Wen-Hung, Lin, Hung-Hsin, Lin, Jen-Kou, Chuang, Chiao-Hsiung, Huang, Tien-Yu, Wang, Horng-Yuan, Wei, Shu-Chen, Wong, Jau-Min
Формат: Artigo
Язык:Inglês
Опубликовано: Korean Association for the Study of Intestinal Diseases 2017
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5683979/
https://ncbi.nlm.nih.gov/pubmed/29142516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2017.15.4.487
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы